Criteria for test drug reduction or discontinuation
ADVERSE REACTION, DISEASES
Reduction or discontinuation of the test drug should be avoided during the trial. However, the investigator will consider dose reduction, suspension, or discontinuation if one of the following occurs:① Occurrence of SAEs related to the test drug;② Adverse reaction (AR) to the tested drugs that cannot be effectively relieved by symptomatic treatment;③ Complications/new onset of other diseases that the test drug may aggravate;④ Significant abnormalities in safety-related laboratory indicators;⑤ Other situations that make investigators believe that dose reduction, suspension, or discontinuation is warranted.